Roche CEO Reassures No Job Cuts Despite Challenges: Report
Roche CEO Reassures No Job Cuts Despite Challenges: Report
Swiss pharmaceutical giant Roche Holding AG (OTC:RHHBY) reportedly has no plans for job cuts despite facing recent challenges in its drug development pipeline.
瑞士药品巨头罗氏(ADR)（场外交易:RHHBY）据报道并没有裁员计划，尽管最近在药物开发管道方面面临挑战。
CEO Thomas Schinecker, in an interview with NZZ am Sonntag, reassured that worker numbers are constant to slightly increasing, reported Reuters.
CEO托马斯·施内克在接受《新苏黎世报》采访时 reassuring workers' numbers are constant to slightly increasing, 据路透社报道。
He also emphasized healthy business and not having a growth problem either. Meanwhile, the report noted Schinecker saying that the company's research and development budget remains stable without expansion.
他还强调了健康的业务，并表示没有增长问题。同时，报道称施内克表示公司的研发预算保持稳定，没有扩张。
Also Read: Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
还读：罗氏-普罗西纳合作的中期帕金森试验未能达到主要终点，但临床益处仍然显现。
Schinecker also provided insights into Roche's pipeline, estimating that the company's anti-obesity drug could hit the market by 2029 or earlier, per the report.
施内克还提供了有关罗氏管道的见解，估计该公司的抗肥胖药物可能在2029年或更早上市。
Addressing the broader economic landscape, Schinecker acknowledged challenges in Europe and China, contrasting them with moderate growth in the U.S.
在谈到更广泛的经济形势时，施内克承认欧洲和中国面临挑战，并将其与美国的适度增长进行了对比。
Price Action: RHHBY shares closed at $35.07 on Friday.
价格动态：RHHBY的股票在周五收于35.07美元。